Search
Lecithin
go.drugbank.com/drugs/DB15834InvestigationalA complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Mixtures: ONE A DAY TABLETCategories: Compounds used in a research, industrial, or household settingVon Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigationalThe human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015. … [L40049] As vWF is normally present in the blood as a stable complex with coagulation factor III, therapeutic vWF products are also available as a combination product with [antihemophilic factor human]
Bezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Products: BEZAFIBRAT 400 RET 1A PHAR, Bezafibrat Genericon retard 400 mg FilmtablettenInsulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigationalIt is a re-engineered version of the ultra long-acting oral basal insulin OI338, with several modifications introduced to significantly extend the half-life. … [L51078] In July 2024, the US FDA rejected the approval of insulin icodec, citing concerns regarding hypoglycemia and the indication being sought for type 1 diabetes mellitus.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class.
Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedThese two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIt is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. … Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label].
Synonyms: D6 tetrabenazine, D6-tetrabenazineRipretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawnIpecac is obtained from the plant _Cephaelis ipecacuanha_ and contains a number of emetic alkaloids including emetine and cephaeline. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency
Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19344ApprovedInvestigationalStreptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains de-O-acetylated saccharides of the capsular antigens of _Streptococcus … pneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).